View Older Stories View More Recent Stories

Aug 23, 2022 09:00AM C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings
Aug 18, 2022 10:05AM Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters
Aug 4, 2022 08:08AM BASEBALL LEGEND BERNIE WILLIAMS TEAMS UP WITH EISAI AND ADVOCACY PARTNERS TO LAUNCH ONE LIVER TO LOVE INITIATIVE TO HELP RAISE AWARENESS ABOUT LIVER CANCER AND THE IMPORTANCE OF LIVER HEALTH
Aug 3, 2022 07:32PM EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC
Jul 27, 2022 08:00AM Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Jul 5, 2022 07:30PM THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Jun 5, 2022 09:00AM Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Jun 2, 2022 07:30PM EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
May 27, 2022 08:08AM Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 9, 2022 07:31PM EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Apr 4, 2022 10:01AM Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease
Mar 31, 2022 08:00AM EISAI TO PRESENT DATA ON NEUROLOGY PORTFOLIO IN THE AREAS OF ALZHEIMER'S DISEASE, SLEEP AND EPILEPSY AT THE 74th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
Mar 30, 2022 07:57AM MEAGAN GOOD SHARES HER SCARE WITH UTERINE CANCER TO ENCOURAGE PEOPLE TO SPOT THE EARLY SIGNS OF ENDOMETRIAL CANCER AS PART OF EISAI AND ADVOCACY PARTNERS' SPOT HER® CAMPAIGN
Mar 21, 2022 07:30PM LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Mar 10, 2022 06:30PM Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting
Mar 3, 2022 06:30PM EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBO
Jan 24, 2022 08:05AM EISAI INC. ANNOUNCES THE APPOINTMENT OF TRICIA BROOKS AS VICE PRESIDENT & HEAD OF OFFICE, GOVERNMENT AFFAIRS AND POLICY
Jan 14, 2022 08:08AM Eisai to Present Research at the 2022 ASCO Gastrointestinal Cancers Symposium in Multiple Tumor Types from its Robust Oncology Portfolio
Dec 23, 2021 06:30PM INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
Dec 7, 2021 11:36AM Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting
Dec 7, 2021 08:35AM #ThisIsMBC "fearLESS" Campaign Portrays Powerful Portraits of People Living fearLESSly with Metastatic Breast Cancer Through Friendship, Community and Making Each Day Count
Dec 7, 2021 08:00AM Eisai Presents Final Results Of Phase IV Elevate Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) At The American Epilepsy Society (AES) 2021 Annual Meeting
Dec 1, 2021 03:15PM Eisai To Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting
Nov 28, 2021 07:15PM European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 11, 2021 12:00PM Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Confer
Nov 11, 2021 11:20AM Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 10, 2021 02:57PM Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD
Nov 4, 2021 08:10AM Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the
Oct 31, 2021 07:41PM The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Oct 17, 2021 07:00PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Sep 27, 2021 07:30PM Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Sep 27, 2021 12:50AM Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sep 13, 2021 08:08AM Data at ESMO Congress 2021 Underscore Depth of Eisai's Oncology Pipeline and Commitment to Cancer Care
Aug 30, 2021 07:42PM Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries
Aug 30, 2021 07:55AM Eisai Announces New Executive Leadership Team at H3 Biomedicine
Aug 11, 2021 07:31PM FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
Aug 5, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery
Jul 29, 2021 04:30PM Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
Jul 22, 2021 07:32AM Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)
Jun 28, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Jun 23, 2021 04:07PM Eisai, Biogen (BIIB) Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 23, 2021 04:06PM Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 9, 2021 08:04AM Eisai to Present Latest DAYVIGO® (lemborexant) CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
May 24, 2021 08:45AM Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients
May 18, 2021 08:34AM Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy
May 17, 2021 08:08AM Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types
Apr 29, 2021 08:08AM Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
Apr 16, 2021 11:53AM Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
Mar 31, 2021 08:08AM Eisai And Advocacy Leaders Team Up To Launch Spot Her - An Initiative That Empowers Women To Help Spot The Signs Of Endometrial Cancer
Mar 10, 2021 08:08AM Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer
View More Recent Stories View Older Stories